Cancer

Delcath Systems Presents Positive Phase II Data on Delcath PHP System in Treatment of Inoperable Liver Metastases

Published in Lab Law Weekly, April 18th, 2008

Delcath Systems, Inc. (NASDAQ: DCTH) announced results from a study of the chemotherapy agent melphalan, delivered via the Company's Percutaneous Hepatic Perfusion (PHP) system, in patients with inoperable liver metastases from primary neuroendocrine tumors at the American Hepato Pancreato Biliary Association (AHPBA) 2008 Annual Meeting held March 27 to 30 in Ft. Lauderdale, Florida.

Patients with diffuse liver disease face limited treatment options and are often given very poor prognoses. The Delcath PHP System was designed to isolate blood flow from the liver, deliver very high doses of anti-cancer agent, then filter a majority of the agent out of the blood from the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2008-04-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry